Enzychem Lifesciences Corporation (KOSDAQ:183490)
South Korea · Delayed Price · Currency is KRW 990.00
-27.00 (-2.65%)
Mar 25, 2026, 7:48 AM KST
Enzychem Lifesciences Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -18,121 | -18,132 | -22,107 | -9,326 | -25,093 | -27,865 |
Depreciation & Amortization | 2,833 | 3,136 | 3,458 | 3,512 | 2,389 | 2,111 |
Loss (Gain) From Sale of Assets | 126.48 | 153.61 | 1.34 | 20 | 10.98 | 13.27 |
Asset Writedown & Restructuring Costs | 3,728 | 3,743 | 145.56 | 32.74 | 4,692 | -16.05 |
Loss (Gain) From Sale of Investments | 16.83 | 16.98 | 2,010 | -3.65 | -3.57 | -4.39 |
Loss (Gain) on Equity Investments | 987.45 | 770.19 | 2,176 | -26.87 | 13.64 | 445.14 |
Stock-Based Compensation | - | - | - | 54.33 | -306.12 | 711.91 |
Provision & Write-off of Bad Debts | -325.56 | 352.17 | -85.85 | 199.23 | -111.75 | 16.95 |
Other Operating Activities | 3,345 | 3,661 | 11,073 | 1,785 | 7,300 | 7,746 |
Change in Accounts Receivable | 4,851 | 3,682 | 3,732 | -4,202 | -1,046 | -1,037 |
Change in Inventory | 530.29 | 234.97 | 2,832 | -4,574 | -1,439 | 822.73 |
Change in Accounts Payable | -836.96 | -1,151 | -3,979 | 4,392 | -333.72 | 1,703 |
Change in Unearned Revenue | - | - | - | 1.94 | 110.39 | 180.05 |
Change in Other Net Operating Assets | -7,745 | -7,479 | 168.7 | -2,122 | -501.84 | -3,417 |
Operating Cash Flow | -10,610 | -11,012 | -573.93 | -10,258 | -14,320 | -18,589 |
Capital Expenditures | -548.42 | -762.68 | -323.82 | -2,248 | -7,957 | -5,818 |
Sale of Property, Plant & Equipment | 49.13 | 49.13 | - | - | 1.34 | 7.5 |
Cash Acquisitions | -100 | -100 | - | -577.53 | - | - |
Divestitures | 10.61 | 0.04 | - | - | - | - |
Sale (Purchase) of Intangibles | 40.48 | 222.3 | -6.7 | -54.19 | -55.45 | -64.45 |
Sale (Purchase) of Real Estate | - | - | -158.69 | - | - | - |
Investment in Securities | 16,284 | 19,281 | 15,363 | 62,350 | -93,370 | -3,665 |
Other Investing Activities | -2,330 | 153.6 | -1,962 | -139.25 | -7,429 | -240.88 |
Investing Cash Flow | 14,868 | 11,927 | 7,359 | 53,562 | -109,233 | -9,729 |
Short-Term Debt Issued | - | 3,150 | 3,983 | 2,554 | 45,671 | 7,140 |
Long-Term Debt Issued | - | 1,197 | - | 1,000 | - | - |
Total Debt Issued | 3,080 | 4,347 | 3,983 | 3,554 | 45,671 | 7,140 |
Short-Term Debt Repaid | - | -3,560 | -2,853 | -25,640 | -26,991 | -6,420 |
Long-Term Debt Repaid | - | -1,127 | -2,446 | -12,666 | -43,889 | -1,559 |
Total Debt Repaid | -2,952 | -4,688 | -5,299 | -38,306 | -70,880 | -7,978 |
Net Debt Issued (Repaid) | 127.66 | -340.55 | -1,316 | -34,752 | -25,210 | -838.54 |
Issuance of Common Stock | - | - | - | - | 153,713 | 30,102 |
Repurchase of Common Stock | -977.08 | -3,004 | -10,822 | - | - | - |
Other Financing Activities | 0 | 0 | -0 | -1.2 | -0 | 0 |
Financing Cash Flow | -849.42 | -3,345 | -12,138 | -35,503 | 128,504 | 29,263 |
Foreign Exchange Rate Adjustments | 93.08 | -32.04 | 186.64 | -13.79 | -83.11 | 12.7 |
Miscellaneous Cash Flow Adjustments | - | - | - | 0 | - | - |
Net Cash Flow | 3,501 | -2,463 | -5,166 | 7,787 | 4,868 | 958.31 |
Free Cash Flow | -11,159 | -11,775 | -897.74 | -12,506 | -22,277 | -24,407 |
Free Cash Flow Margin | -18.04% | -17.38% | -1.16% | -16.45% | -83.63% | -106.23% |
Free Cash Flow Per Share | -144.53 | -152.29 | -10.96 | -147.25 | -282.63 | -483.37 |
Cash Interest Paid | 201.83 | 210.92 | 240.83 | 478.22 | -174.26 | 366.93 |
Cash Income Tax Paid | - | -251.58 | -317.1 | 867.51 | 76.33 | 11.49 |
Levered Free Cash Flow | -1,991 | -3,106 | -4,554 | -13,645 | -32,617 | -22,543 |
Unlevered Free Cash Flow | -1,873 | -2,980 | -4,405 | -13,258 | -26,348 | -16,600 |
Change in Working Capital | -3,200 | -4,713 | 2,754 | -6,504 | -3,210 | -1,748 |